HSP90B1 and neoplasm: Because the gp96 vaccine was completely derived from an autologous tumor and the median number of injection times in this study was 6, we can conclude that patients with low tumor load or a low level of gp96 expression may not be suitable recipients of the gp96 tumor vaccine.